2-cyano-3-(4-nitrophenyl)-N-[(1R)-1-phenylethyl]prop-2-enamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 2-cyano-3-(4-nitrophenyl)-N-[(1R)-1-phenylethyl]prop-2-enamide
• 化学式: C18H15N3O3
• 分子量: 321.3
• InChiKey: RYYNDHCHTCVQJH-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  98.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Natural-killer/T-cell lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy
  申请人：SINGAPORE HEALTH SERVICES PTE LTD

  公开号：US10378062B2

  公开（公告）日：2019-08-13

  Natural-KilleifT-Cell Lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy. The invention relates to a method for predicting Natural Killer T-cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject comprising testing for JAK mutations. The invention also relates to a method of screening for candidate agents capable of treating NKTCL using a cell line comprising at least one JAK mutation. The invention includes an NKTCL animal model comprising at least one JAK mutation. The invention also includes JAK inhibitors for treating NKTCL.

  天然杀伤T细胞淋巴瘤（NKTCL）易感性预测、诊断和治疗。本发明涉及一种预测天然杀伤T细胞淋巴瘤（NKTCL）易感性和/或诊断受试者NKTCL的方法，包括检测JAK突变。本发明还涉及一种利用包含至少一种 JAK 突变的细胞系筛选能够治疗 NKTCL 的候选药物的方法。本发明包括一种包含至少一种 JAK 突变的 NKTCL 动物模型。本发明还包括用于治疗NKTCL的JAK抑制剂。
• EP2782562A2
  申请人：——

  公开号：EP2782562A2

  公开（公告）日：2014-10-01
• NATURAL-KILLER/T-CELL LYMPHOMA (NKTCL) SUSCEPTIBILITY PREDICTION, DIAGNOSIS AND THERAPY
  申请人：Singapore Health Services Pte Ltd

  公开号：EP2782562B1

  公开（公告）日：2016-12-21
• METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS
  申请人：Priebe Anna

  公开号：US20110275577A1

  公开（公告）日：2011-11-10

  The present invention relates to caffeic acid analog compounds and methods which may be useful for regeneration, cellular programming, and the treatment of dermatologic, gynecologic, and genital diseases such as inflammatory dermatologic conditions, dysplasia, neoplasia, in situ carcinoma, invasive carcinoma, lichen sclerosus, lichen planus, vaginal dysplasia, vaginal carcinoma, vulvar dysplasia, vulvar carcinoma, cervical dysplasia, cervical carcinoma, and Kaposi's sarcoma.
• INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION
  申请人：Priebe Waldemar

  公开号：US20130129675A1

  公开（公告）日：2013-05-23

  Methods of modulating the INF-induced STAT3 activation in a patient in need-thereof are provided for the treatment of disease. The methods comprise the step of administrating to a patient the combination of a therapeutically effective amount of interferon including INF-α and/or INF-β in combination with a STAT3 inhibitor.